Immediate response mouse models

Iwamura and Ueda [386] described compound (611) as a CB2 selective inverse agonist in a patent application. The potential therapeutic roles of CB2 antagonists are not clearly defined at the moment, although roles in regulation of the immune system and inflammation have been widely proposed. This patent application describes that activity of compound (611) in a mouse model of asthma, in which the compound suppressed immediate and late-phase asthmatic response and airway hyper-responsiveness. 

Vesicant wounds undoubtedly initiate an immune response due to the nature of the wounds. This response begins almost immediately when the initial events promote capillary permeability, and the interstitium becomes inundated with circulatory components. And the wound site itself is subject to secondary infections by pathogens that reach the open wound area. These pathogens may be responsible for the large number of infiltrating cells that are seen in the mouse ear vesicant model 7 days post-SM exposure (Figure 41.3). 

---